TSE:RVX

Resverlogix Competitors

C$0.86
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$0.85
Now: C$0.86
C$0.88
50-Day Range
C$0.85
MA: C$0.91
C$1.02
52-Week Range
C$0.56
Now: C$0.86
C$1.52
Volume42,574 shs
Average Volume57,252 shs
Market CapitalizationC$202.07 million
P/E Ratio78.18
Dividend YieldN/A
BetaN/A

Competitors

Resverlogix (TSE:RVX) Vs. APS, BU, TH, BLU, NRI, and PLI

Should you be buying RVX stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Resverlogix, including Aptose Biosciences (APS), Burcon NutraScience (BU), Theratechnologies (TH), BELLUS Health (BLU), Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI), and ProMetic Life Sciences (PLI).

Resverlogix (TSE:RVX) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Resverlogix and Aptose Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
Aptose Biosciences00203.00

Aptose Biosciences has a consensus target price of C$12.00, indicating a potential upside of 81.54%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Resverlogix.

Profitability

This table compares Resverlogix and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
Aptose BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares Resverlogix and Aptose Biosciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79

Aptose Biosciences is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Resverlogix (TSE:RVX) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Resverlogix and Burcon NutraScience, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
Burcon NutraScience00103.00

Burcon NutraScience has a consensus target price of C$5.00, indicating a potential downside of 7.75%. Given Burcon NutraScience's higher possible upside, analysts plainly believe Burcon NutraScience is more favorable than Resverlogix.

Profitability

This table compares Resverlogix and Burcon NutraScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
Burcon NutraScienceN/AN/AN/A

Earnings and Valuation

This table compares Resverlogix and Burcon NutraScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00

Burcon NutraScience has higher revenue and earnings than Resverlogix. Resverlogix is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Resverlogix on 4 of the 5 factors compared between the two stocks.

Resverlogix (TSE:RVX) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares Resverlogix and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
TheratechnologiesN/AN/AN/A

Earnings and Valuation

This table compares Resverlogix and Theratechnologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
TheratechnologiesC$66.05 million6.78C$-27,589,254.00C($0.29)-16.22

Resverlogix has higher earnings, but lower revenue than Theratechnologies. Theratechnologies is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Resverlogix and Theratechnologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
Theratechnologies02002.00

Theratechnologies has a consensus target price of C$3.75, indicating a potential downside of 21.38%. Given Theratechnologies' higher possible upside, analysts plainly believe Theratechnologies is more favorable than Resverlogix.

Resverlogix (TSE:RVX) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Resverlogix and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
BELLUS HealthN/AN/AN/A

Valuation and Earnings

This table compares Resverlogix and BELLUS Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
BELLUS HealthC$15,000.0028,462.44C$-42,145,306.00C($0.54)-10.13

Resverlogix has higher earnings, but lower revenue than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Resverlogix and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
BELLUS Health01202.67

Resverlogix (TSE:RVX) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Resverlogix and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Valuation and Earnings

This table compares Resverlogix and Nuvo Pharmaceuticals Inc. (NRI.TO)'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.38C$-6,980,844.00C($0.61)-58.64

Resverlogix has higher earnings, but lower revenue than Nuvo Pharmaceuticals Inc. (NRI.TO). Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Resverlogix and Nuvo Pharmaceuticals Inc. (NRI.TO), as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Resverlogix (TSE:RVX) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, valuation, earnings and analyst recommendations.

Profitability

This table compares Resverlogix and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ResverlogixN/AN/AN/A
ProMetic Life SciencesN/AN/AN/A

Valuation and Earnings

This table compares Resverlogix and ProMetic Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ResverlogixN/AN/AN/AC$0.0178.18
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A

Resverlogix has higher earnings, but lower revenue than ProMetic Life Sciences. ProMetic Life Sciences is trading at a lower price-to-earnings ratio than Resverlogix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Resverlogix and ProMetic Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Resverlogix0000N/A
ProMetic Life Sciences0000N/A

Summary

Resverlogix beats ProMetic Life Sciences on 2 of the 3 factors compared between the two stocks.


Resverlogix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APS
Aptose Biosciences
1.3$6.61flatC$587.53 millionN/A-9.79
BU
Burcon NutraScience
1.2$5.42flatC$580.49 millionC$12,045.005,420.00
Theratechnologies logo
TH
Theratechnologies
0.7$4.77flatC$447.62 millionC$66.05 million-16.22Upcoming Earnings
News Coverage
BLU
BELLUS Health
0.5$5.45flatC$426.94 millionC$15,000.00-10.13Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.95flatC$409.34 millionC$76.09 million-58.64News Coverage
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.77flatC$292.92 millionC$52.78 million-1.31Gap Up
MDNA
Medicenna Therapeutics
0.5$5.08flatC$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99flatC$259.90 millionN/A-8.91News Coverage
Gap Down
EMC
Emblem
0.5$1.88flat$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62flatC$245.11 millionC$3,000.00-6.26
ATE
Antibe Therapeutics
1.3$4.88flatC$222.07 millionC$9.33 million-6.20Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.82flatC$203.34 millionC$170,000.00-10.24
HBP
Helix BioPharma
0.5$0.92flatC$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41flatC$123.03 millionC$17.18 million-72.01News Coverage
Gap Up
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.68flatC$88.79 millionC$81,000.0025.19Gap Down
NVH
Novoheart
0.5$0.53flatC$79.23 millionC$423,500.00-13.95
PMN
ProMIS Neurosciences
0.5$0.22flatC$67.31 millionC$1,787.00-11.00
PDP
Pediapharm
0.5$0.30flatC$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.55flatC$60.20 millionC$11.64 million-10.78News Coverage
Gap Up
SBM
Sirona Biochem
0.5$0.38flatC$58.80 millionC$123,870.00-29.23
COV
Covalon Technologies
0.6$1.41flatC$37.44 millionC$23.84 million-5.92News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.29flatC$34.02 millionC$13.02 million-0.42
IGX
IntelGenx Technologies
0.9$0.57flatC$30.87 millionC$1.54 million-8.77News Coverage
QPT
Quest PharmaTech
0.8$0.11flatC$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72flatC$21.65 millionC$16.14 million21.82News Coverage
CTX
Crescita Therapeutics
0.6$0.86flatC$17.76 millionC$15.64 million430.00
KNE
Kane Biotech
0.4$0.17flatC$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27flatC$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09flatC$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06flatC$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60flatC$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39flatC$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49flatC$9.07 millionN/A-2.92News Coverage
Gap Down
ICO
iCo Therapeutics
0.5$0.11flatC$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36flatC$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$6.40flatC$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.00
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.